Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
Open Access
- 3 August 2023
- journal article
- research article
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (5)
Abstract
Background: The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mgversusplacebo every 2 weeks for 52 weeks (QUEST) and dupilumab 300 mg up to an additional 96 weeks (TRAVERSE) in patients ≥12 years of age with uncontrolled, moderate-to-severe asthma. Overall, safety was consistent with the known dupilumab safety profile. Thispost hocanalysis assessed long-term dupilumab efficacy for up to 3 years by exacerbation history.Patients and methods: Unadjusted annualised severe exacerbation rates (AER) and change from parent study baseline (PSBL) in pre-bronchodilator forced expiratory volume in 1 s (FEV1) and 5-item Asthma Control Questionnaire (ACQ-5) score were assessed in patients with PSBL eosinophils ≥150 cells·µL−1or fractional exhaled nitric oxide ≥20 ppb and 1 (n=624), 2 (n=344), or ≥3 (n=311) exacerbations in the year before enrolment in QUEST.Results: In all three groups, dupilumab treatment progressively reduced AER range to 0.17–0.30 during TRAVERSE (Weeks 48–96), increased pre-bronchodilator FEV1range by 0.28–0.49 L by Week 96 and improved asthma control (reduced ACQ-5 score range by 1.51–2.03 by Week 48). For patients who first received dupilumab upon TRAVERSE enrolment, AER decreased, and lung function and asthma control improved rapidly, as was observed upon initiation of dupilumab in QUEST. Dupilumab was efficacious regardless of exacerbation history.Conclusion: For patients with uncontrolled, moderate-to-severe asthma with elevation of at least one type 2 biomarker, dupilumab treatment provides sustained, long-term reduction of exacerbation rates and improvements in lung function and asthma control irrespective of exacerbation history.Keywords
Funding Information
- Sanofi (NCT02134028, NCT02414854)
- Regeneron Pharmaceuticals (NCT02134028, NCT02414854)
This publication has 18 references indexed in Scilit:
- Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Type 2 inflammation in asthma — present in most, absent in manyNature Reviews Immunology, 2014
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal miceProceedings of the National Academy of Sciences, 2014
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genesProceedings of the National Academy of Sciences, 2014
- Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthmaJournal of Allergy and Clinical Immunology, 2012
- Asthma Control Questionnaire in children: validation, measurement properties, interpretationEuropean Respiratory Journal, 2010
- Severe Exacerbations and Decline in Lung Function in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Recent asthma exacerbations: A key predictor of future exacerbationsRespiratory Medicine, 2007
- The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UKPrimary Care Respiratory Journal, 2007
- Mild Exacerbations and Eosinophilic Inflammation in Patients With Stable, Well-Controlled Asthma After 1 Year of Follow-upChest, 2001